We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Tilray, Inc. (TLRY) Gains As Market Dips: What You Should Know
Read MoreHide Full Article
In the latest trading session, Tilray, Inc. (TLRY - Free Report) closed at $22.04, marking a +1.9% move from the previous day. The stock outpaced the S&P 500's daily loss of 0.32%. Meanwhile, the Dow lost 0.32%, and the Nasdaq, a tech-heavy index, lost 0.11%.
Coming into today, shares of the company had lost 15.38% in the past month. In that same time, the Medical sector gained 0.15%, while the S&P 500 gained 4.4%.
Investors will be hoping for strength from TLRY as it approaches its next earnings release. In that report, analysts expect TLRY to post earnings of -$0.10 per share. This would mark year-over-year growth of 79.59%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $61.86 million, up 18.74% from the year-ago period.
TLRY's full-year Zacks Consensus Estimates are calling for earnings of -$0.38 per share and revenue of $296.19 million. These results would represent year-over-year changes of +82.33% and +40.72%, respectively.
It is also important to note the recent changes to analyst estimates for TLRY. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. TLRY is currently a Zacks Rank #3 (Hold).
The Medical - Drugs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 175, which puts it in the bottom 32% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Tilray, Inc. (TLRY) Gains As Market Dips: What You Should Know
In the latest trading session, Tilray, Inc. (TLRY - Free Report) closed at $22.04, marking a +1.9% move from the previous day. The stock outpaced the S&P 500's daily loss of 0.32%. Meanwhile, the Dow lost 0.32%, and the Nasdaq, a tech-heavy index, lost 0.11%.
Coming into today, shares of the company had lost 15.38% in the past month. In that same time, the Medical sector gained 0.15%, while the S&P 500 gained 4.4%.
Investors will be hoping for strength from TLRY as it approaches its next earnings release. In that report, analysts expect TLRY to post earnings of -$0.10 per share. This would mark year-over-year growth of 79.59%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $61.86 million, up 18.74% from the year-ago period.
TLRY's full-year Zacks Consensus Estimates are calling for earnings of -$0.38 per share and revenue of $296.19 million. These results would represent year-over-year changes of +82.33% and +40.72%, respectively.
It is also important to note the recent changes to analyst estimates for TLRY. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. TLRY is currently a Zacks Rank #3 (Hold).
The Medical - Drugs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 175, which puts it in the bottom 32% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.